ASTH
Astrana Health, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net leverage (pro forma trailing twelve-month) non-GAAP | 2.3 | Q1 2026 | — |
| adjusted EBITDA non-GAAP | $66.3M | Q1 FY2026 call | — |
| G&A as a percentage of revenue | 6.4% | Q1 FY2026 call | — |
| members in value-based care arrangements | 1.55M | Q1 FY2026 call | — |
| net leverage non-GAAP | 2.3 | Q1 FY2026 call | — |
| Remaining availability under share repurchase plan | $35.9M | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASTH
this stock
Astrana Health, Inc.
|
$2.74B | +98.2% | +45.9% | 80.6 | 4.2% |
|
HCA
HCA Healthcare, Inc.
|
$92.52B | -10.5% | +7.1% | 14.1 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.16B | -12.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.55B | +2.5% | -2.3% | 10.6 | 4.7% |
|
DVA
Davita Inc.
|
$15.08B | +106.8% | +6.5% | 21.9 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASTH | +13.0% | +34.0% | +74.2% | +6.0% | +98.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +11.6% | +35.2% | +66.2% | +6.2% | +89.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.